Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.

摘要: Influenza virus of the H7N2 subtype has been introduced into noncommercial poultry in United States, and this probably resulted incidents transmission to humans, documented 2002 2003. This could be considered a potential threat public health if it acquired person-to-person transmissibility. A favored approach for global pandemic preparedness includes development prepandemic vaccines any virus. To end, we created high-growth reassortant (H7N2-PR8) containing genes hemagglutinin neuraminidase from low-pathogenicity (H7N2) strain remaining six human vaccine (H1N1). The was evaluated assess its antigenicity, safety, protective efficacy using mouse model. Antigenicity studies ferret antibodies raised against H7N2-PR8 indicated that confers broad cross-reactivity with divergent H7 viruses different years lineages. Mice chickens inoculated high doses supported replication but survived, indicating is comparable other avian low pathogenicity. H7N2-PR8, mice were immunized two formalin-inactivated alone or alum. Vaccinated subsequently challenged highly pathogenic homologous heterologous lineages A/Canada/444/04 (H7N3) A/Netherlands/219/03 (H7N7) showed pronounced reduction wild-type replication. These indicate immunogenic, safe, animal models; these are essential attributes qualify phase I clinical trials as vaccine.